Josh Silvertown

Biography

Dr. Josh Silvertown is a leading authority in relaxin cancer biology. He has over 17 years of experience in preclinical drug research and development and is the lead inventor of Armour's relaxin-antagonist technology. During his years in translational and biomedical research, Josh published over 30 scientific works, including publications in notable endocrinology and oncology journals, and is an inventor on 23 issued or pending patents. Josh has had experience in executive management (corporate and global business development) and consulting (clinical research, strategy, and medical communications) roles for biopharma, biotech and medical device companies in Canada, the US and Europe. Josh spent three years as an NSERC Post-Doctoral Fellow conducting prostate cancer research at the Ontario Cancer Institute, University Health Network in Toronto. Josh is a graduate of the Ivey School of Business at Western University, where he completed an MBA, specializing in the Health Sector as a Canadian Institute of Health Research "Science-to-Business" Fellow. He also holds a PhD in Biomedical Sciences and an Honours BSc in Molecular Biology and Genetics from the University of Guelph. Josh is an Action Canada Fellow of 2004 and was chosen as a "Top 40 Under 40" in the medtech sector by the Medical Device and Diagnostic Industry (MDDI) in 2012.  Dr. Josh Silvertown is a leading authority in relaxin cancer biology. He has over 17 years of experience in preclinical drug research and development and is the lead inventor of Armour's relaxin-antagonist technology. During his years in translational and biomedical research, Josh published over 30 scientific works, including publications in notable endocrinology and oncology journals, and is an inventor on 23 issued or pending patents. Josh has had experience in executive management (corporate and global business development) and consulting (clinical research, strategy, and medical communications) roles for biopharma, biotech and medical device companies in Canada, the US and Europe. Josh spent three years as an NSERC Post-Doctoral Fellow conducting prostate cancer research at the Ontario Cancer Institute, University Health Network in Toronto. Josh is a graduate of the Ivey School of Business at Western University, where he completed an MBA, specializing in the Health Sector as a Canadian Institute of Health Research "Science-to-Business" Fellow. He also holds a PhD in Biomedical Sciences and an Honours BSc in Molecular Biology and Genetics from the University of Guelph. Josh is an Action Canada Fellow of 2004 and was chosen as a "Top 40 Under 40" in the medtech sector by the Medical Device and Diagnostic Industry (MDDI) in 2012. 

Research Interest

Biochemistry